熱門資訊> 正文
Nuwellis获得USPTO双腔导管专利批准
2026-04-28 22:05
- Nuwellis (NUWE) announced on Tuesday that it received a Notice of Allowance from the USPTO for a new patent on its dual-lumen catheter used in ultrafiltration therapy, aimed at improving blood flow and reducing treatment complications.
- The catheter comes with an adjustable, flexible design that doctors can customize during treatment, ensuring smoother usage and consistent performance across patients.
- Once the patent is officially approved, it is expected to strengthen Nuwellis’ (NUWE) product lineup and support the expansion of ultrafiltration therapy in hospitals and outpatient settings.
- The stock is trading ~3% lower at ~$1.13.
- Source: Press Release
More on Nuwellis
- Nuwellis, Inc. (NUWE) Q4 2025 Earnings Call Transcript
- Quant snapshot: Avino Silver & Gold, Harmony Gold lead strong buys as Angel Studios, Exagen lag
- Nuwellis to acquire Rendiatech, raises $5 mln in private placement
- Seeking Alpha’s Quant Rating on Nuwellis
- Historical earnings data for Nuwellis
推薦文章
新股申購 | 青梅零食龍頭溜溜梅今啟招股，一手入場費4401.96港元
華盛早報 | 黃仁勛訪韓行程曝光！盯上機器人賽道；臺積電魏哲家：數年內都無法滿足芯片需求；微信聯手華為、榮耀推出A2A功能
港股5月回購透視：合計回購220億港元 京東健康、藥明康德等年內首度回購
美債市場「野獸」咆哮迴歸 凸性對衝恐加劇波動
高盛預測：SpaceX人工智能業務2030年營收將暴漲100倍
Redwire獲Astrobiome Space合同 將發射世界首個商業太空温室
「超級IPO浪潮」來襲！SpaceX定於下周五上市，投資者該如何把握歷史性機遇？（附股）
比特幣價格接連創出新低，堅定持倉大户開始拋售離場
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
